Most companies want to avoid FDA warning letters. To help medical device companies identify violations that might lead to a warning letter, this post will dive deeply into which specific types of violations are often found in warning letters that FDA issues.
As you probably know, the FDA has a formal process for evaluating inspection records and other materials to determine whether issuing a warning letter is appropriate. Those procedures can be found in chapter 4 of FDA’s Regulatory Procedures Manual. Section 4-1-10 of that chapter requires that warning letters include specific legal citations, in addition to plain English explanations of violations. The citations are supposed to make reference to both the statute and any applicable regulations.
As a consequence, to understand the content of the warning letters, we need to search for both statutory references as well as references to regulations. Because statutes are deliberately drafted to be broader in their language, references to the regulations tend to be more meaningful.
To display the regulatory citations found, I created a word cloud to show the frequency with which different regulatory references are used in the medical device warning letters during the calendar years 2017 through 2021.
If you are unfamiliar with a word cloud, it’s a way to present words, or in this case references to regulations, in a font size that is proportionate with their frequency.
I recognize that you may not have memorized all of the CFR references. Thus, the following table presents the exact same information, but with the CFR part and the CFR title of the regulation included, as well as the specific frequency listed in the “count” column.
|Number||Count||CFR Part||CFR Title|
|820.30||131||Good Manufacturing Practices||Design controls.|
|820,100||99||Good Manufacturing Practices||Corrective and preventive action.|
|803.17||87||Medical Device Reporting||What are the requirements for developing, maintaining, and implementing written MDR procedures that apply to me?|
|820,198||84||Good Manufacturing Practices||Complaint files.|
|820.7||59||Good Manufacturing Practices||Production and process controls.|
|820.75||57||Good Manufacturing Practices||Process validation.|
|820.8||54||Good Manufacturing Practices||Receiving, in-process, and finished device acceptance.|
|807.81||46||Establishment Registration and Device Listing||When a premarket notification submission is required.|
|820.5||46||Good Manufacturing Practices||Purchasing controls.|
|820.9||45||Good Manufacturing Practices||Nonconforming product.|
|803.5||39||Medical Device Reporting||If I am a manufacturer, what reporting requirements apply to me?|
|820,184||31||Good Manufacturing Practices||Device history record.|
|820.22||30||Good Manufacturing Practices||Quality audit.|
|803.3||23||Medical Device Reporting||How does the FDA define the terms used in this part?|
|820.2||22||Good Manufacturing Practices||Management responsibility.|
|820.4||21||Good Manufacturing Practices||Document controls.|
|807.39||21||Establishment Registration and Device Listing||Misbranding by reference to establishment registration or to registration number.|
|820.25||21||Good Manufacturing Practices||Personnel.|
|820,181||20||Good Manufacturing Practices||Device master record.|
|820.72||17||Good Manufacturing Practices||Inspection, measuring, and test equipment.|
|1271.3||11||Human Cell and Tissue Base Products||How does the FDA define important terms in this part?|
|806.1||10||Reports of Corrections and Removals||Reports of corrections and removals.|
|1271.1||10||Human Cell and Tissue Base Products||Are my HCT / P’s regulated solely under section 361 of the PHS Act and the regulations in this part, and if so what must I do?|
|890.9||10||Physical Medicine Devices||Limitations of exemptions from section 510 (k) of the Federal Food, Drug, and Cosmetic Act (the act).|
|884,298||10||Obstetrical and Gynecological Devices||Telethermographic system.|
|803.2||9||Medical Device Reporting||How do I complete and submit an individual adverse event report?|
|812.2||9||Investigational Device Exemptions||Applicability.|
|812.14||8||Investigational Device Exemptions||Records.|
|890,538||8||Physical Medicine Devices||Powered exercise equipment.|
|211,192||7||Drug GMPs||Production record review.|
|807.97||6||Establishment Registration and Device Listing||Misbranding by reference to premarket notification.|
|820.25||6||Good Manufacturing Practices||Statistical techniques.|
|820.12||6||Good Manufacturing Practices||Device labeling.|
|890.55||6||Physical Medicine Devices||Infrared lamp.|
|58.33||6||Good Laboratory Practices||Study director.|
|814.82||6||Premarket Approval||Postapproval requirements.|
The presentation is duller, but the information is probably more useful this way. I cut the plain English table off at six citations, as I considered five and under too idiosyncratic to bother listing.
The FDA keeps copies of warning letters from the most recent five years on its website, so presently they have 2017 through 2021. The first trick is to make sure that we have all the device warning letters. It’s not as simple as taking all the warning letters issued by the Center for Devices and Radiological Health. Different offices across FDA can issue warning letters, so we need to check, for example, for warning letters issued by the district offices in the field that relate to medical devices. By my count, over the relevant period, there were 236 device-focused letters.
Most of the time, the FDA does not stop at just citing the statute. To the agency’s credit, they often recite the more specific regulation they believe to be violated. Doing so gives the recipient of the letter a better understanding of exactly to what FDA is objecting. Out of the 236 warning letters, FDA cited regulations in 180. By subtraction, that means there were 56 warning letters where the agency only cited a statute, not a regulation.
A statutory section commonly cited without a regulation is section 501 (f) (1) (b) of the Federal Food, Drug, and Cosmetic Act, which defines an adulterated medical device. When a device is marketed without premarket review, the FDA will commonly cite both the adulteration and misbranding statutory provisions. And in those cases, it’s not unusual for the FDA to omit any reference to any specific regulation. As a result, it’s likely that many of the 56 warning letters that do not include a reference to a regulation addressed a failure to get premarket approval or clearance of some sort. In particular, my analysis found 98 warning letters that included a reference to the adulteration provision. There are other violations besides failure to file a premarket submission that can lead to adulteration, so it is not surprising that number is larger than 56.
When it came to searching for CFR sections, those who drafted the warning letters were somewhat inconsistent with just how deep a reference should be, ie whether it should be to the section, the subsection, the paragraph, etc. As a result, I shortened each of the references to the section. I ignored references that were merely to parts of the CFR, as they were not specific enough to be useful.
If you read last month’s post, you will already be aware that these data include years that are statistically anomalous. The years 2020 and 2021 were COVID years during which FDA essentially shut off routine facility inspections. As a result, the agency wasn’t generating inspectional results that would lead to a warning letter. Instead, many of the warning letters stemmed from such issues as unapproved laboratory tests for COVID and adulterated personal protective equipment, not based on a specific FDA facility inspection.
Immediately prior to COVID, during the Trump administration, the FDA was sending fewer warning letters compared to under the Obama administration. Indeed, last month I went back 10 years to get results that were more typical of FDA’s performance. But I didn’t have that opportunity with regard to warning letters, as the agency archives warning letters once they are five years old. Thus, in a sense this entire data set of warning letters is statistically anomalous when considered in the fuller context of the last several decades of FDA warning letters.
But with that historical fact noted, many of the results are consistent with the analysis last month of the inspectional data. Eight of the top 10 violations are good manufacturing practice violations. That should not be surprising. The inspection process that focuses on good manufacturing practices (“GMPs”) is typically the primary pipeline that feeds the warning letter process.
Among the very top citations are design controls, CAPA, complaint files, production and process controls and, outside of GMPs, a failure to report adverse events. None of that should surprise anyone. That’s been the standard fare for many years.
Toward the top is 807.81, the regulatory citation FDA uses when a company should have filed a 510 (k) but didn’t. It’s not surprising that citation is toward the top during years in which enforcing against unapproved COVID tests would have been a high priority, although many of those products fell into the adulterated / misbranded statutory citations referenced above.
To me, the most interesting stuff is not the very top of the list, but the middle of the list. Notice that the top violations are not that different in terms of the frequency from the second tier. In areas like purchasing controls, nonconforming product and device history files ranked very highly. I’ve been doing this for many years, and I was surprised that device history files were so high on the list. I knew they were a common inspectional finding, but I was surprised that so many warning letters listed that as a defect.
Which brings me to one last important point that is honestly not captured in this data. The conventional wisdom is that the first item or two listed in the warning letter are the items that motivated the issuance of the warning letter, but once the agency decides to send a letter, they throw in other defects that may not have themselves been all that significant . It’s possible that topics like device history files might fit into that category, but I don’t have any data on that. This analysis does not distinguish between regulatory citations listed first in a warning letter and those that follow.
Like the inspectional observation data analyzed last month, these data can be considered important inputs into a quality system as they identify issues that the FDA considers to be among the most significant. Next month, I will dive into a third element of quality data, a root cause analysis of medical device recalls. Together with the FDA enforcement data, all of these data points to critical factors that medical device companies collectively have been struggling with, and should perhaps prioritize in remediation.
Attorney Bradley Merrill Thompson is the Chairman of the Board and Chief Data Scientist for EBG Advisors and a Member of the Firm at Epstein Becker Green.
The opinions expressed in this publication are those of the author.